Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Butyrophilin subfamily 3A (BTN3A) family (BTN3A)
- Target
- BTN3A
- Molecular classification
- Immunoglobulin superfamily, B7 family–related protein, Receptor (cell-surface and intracellular domains)
01
Overview
The butyrophilin subfamily 3A (BTN3A) family consists of BTN3A1, BTN3A2, and BTN3A3, cell surface receptors belonging to the immunoglobulin superfamily and structurally related to the B7 family. BTN3A1 is best known for its intracellular B30.2 domain, which binds phosphoantigens and activates human Vγ9Vδ2 γδ T cells—a process involved in immune surveillance, infection control, and anti-tumor immunity. BTN3A2 and BTN3A3 function as co-regulators, enhancing BTN3A1 activity; BTN3A2 lacks the B30.2 domain. The BTN3A molecules are widely expressed in immune cells and epithelial tissues, with dynamic roles in T cell (both αβ and γδ) and NK cell regulation, as well as links to inflammation, infection, and cancer. Ongoing research targets these molecules for immunotherapy and cancer treatment[2][3][4][5][6][7][8].
- Other names
- Butyrophilin-3A1Butyrophilin-3A2Butyrophilin-3A3BTN3A familyBTF3ACD277
02
Mechanism of action
Activation of human Vγ9Vδ2 T cells by phosphoantigen presentation via BTN3A1 cytoplasmic B30.2 domain; Modulation (co-stimulation/co-inhibition) of T cell activation by BTN3A engagement
03
Biological functions
Immune regulation (activation, inhibition)γδ T cell (Vγ9Vδ2) activation by phosphoantigen presentationRegulation of αβ T cell responsesCo-stimulation and co-inhibition of immune cellsModulation of NK cell and dendritic cell activityRegulation of type I interferon responses
04
Disease associations
Cancer (expression in tumors, influences tumor immunity)Infection (role in immune response to infected cells)Inflammation (controls tissue inflammatory signals)Other (potential role in autoimmune diseases and viral infections, preclinical evidence)
05
Safety considerations
As immunomodulatory molecules, therapeutic targeting could result in risks such as excessive immune activation, cytokine release syndrome, or autoimmunity (inferred from similar targets and functional roles)Potential off-target modulation of general immune responses leading to inflammatory or autoimmune side effects
06
Interacting drugs
Zoledronate (an aminobisphosphonate; increases intracellular phosphoantigens, leading to BTN3A1-mediated activation of γδ T cells)
1 more in the full profile.
07
Biomarkers
BTN3A1 expression in tumor tissues (prognostic & potential predictive marker for immune therapy)γδ T cell activation status (functional biomarker for BTN3A engagement)
Beyond the preview
Go deeper on Butyrophilin subfamily 3A (BTN3A) family (BTN3A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Butyrophilin subfamily 3A (BTN3A) family (BTN3A).